203 related articles for article (PubMed ID: 34709602)
1. Zimberelimab: First Approval.
Markham A
Drugs; 2021 Nov; 81(17):2063-2068. PubMed ID: 34709602
[TBL] [Abstract][Full Text] [Related]
2. Sintilimab: First Global Approval.
Hoy SM
Drugs; 2019 Feb; 79(3):341-346. PubMed ID: 30742278
[TBL] [Abstract][Full Text] [Related]
3. Camrelizumab: First Global Approval.
Markham A; Keam SJ
Drugs; 2019 Aug; 79(12):1355-1361. PubMed ID: 31313098
[TBL] [Abstract][Full Text] [Related]
4. Tislelizumab: First Approval.
Lee A; Keam SJ
Drugs; 2020 Apr; 80(6):617-624. PubMed ID: 32185681
[TBL] [Abstract][Full Text] [Related]
5. Dostarlimab: First Approval.
Markham A
Drugs; 2021 Jul; 81(10):1213-1219. PubMed ID: 34106455
[TBL] [Abstract][Full Text] [Related]
6. Penpulimab: First Approval.
Dhillon S
Drugs; 2021 Dec; 81(18):2159-2166. PubMed ID: 34813051
[TBL] [Abstract][Full Text] [Related]
7. Envafolimab: First Approval.
Markham A
Drugs; 2022 Feb; 82(2):235-240. PubMed ID: 35122636
[TBL] [Abstract][Full Text] [Related]
8. PD-1 Blockers.
Wolchok JD
Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
[TBL] [Abstract][Full Text] [Related]
9. Current Status and Prospects of Camrelizumab, A Humanized Antibody Against Programmed Cell Death Receptor 1.
Song H; Liu X; Jiang L; Li F; Zhang R; Wang P
Recent Pat Anticancer Drug Discov; 2021; 16(3):312-332. PubMed ID: 33563158
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab: first global approval.
Poole RM
Drugs; 2014 Oct; 74(16):1973-1981. PubMed ID: 25331768
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab (Keytruda) for first-line treatment of metastatic NSCLC.
Med Lett Drugs Ther; 2017 Jan; 59(1513):22-23. PubMed ID: 28118650
[No Abstract] [Full Text] [Related]
12. Toripalimab: First Global Approval.
Keam SJ
Drugs; 2019 Apr; 79(5):573-578. PubMed ID: 30805896
[TBL] [Abstract][Full Text] [Related]
13. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic.
Kang SP; Gergich K; Lubiniecki GM; de Alwis DP; Chen C; Tice MAB; Rubin EH
Ann Oncol; 2017 Jun; 28(6):1388-1398. PubMed ID: 30052728
[No Abstract] [Full Text] [Related]
15. Cadonilimab: First Approval.
Keam SJ
Drugs; 2022 Aug; 82(12):1333-1339. PubMed ID: 35986837
[TBL] [Abstract][Full Text] [Related]
16. Clinical Trials of PD-1 and PD-L1 inhibitors in NSCLC.
Clin Adv Hematol Oncol; 2014 Jan; 12(1 Suppl 1):14-6. PubMed ID: 24852398
[No Abstract] [Full Text] [Related]
17. [Immunotherapy in lung cancer: checkpoint inhibitors].
Wehler T; Wehler B; Stehle I
Dtsch Med Wochenschr; 2015 Dec; 140(24):1835-8. PubMed ID: 26625234
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable.
Prasad V; Kaestner V
Semin Oncol; 2017 Apr; 44(2):132-135. PubMed ID: 28923211
[TBL] [Abstract][Full Text] [Related]
19. Immuno-oncology drugs jostle for first-line setting.
Mullard A
Nat Rev Drug Discov; 2016 Nov; 15(11):738. PubMed ID: 27807351
[No Abstract] [Full Text] [Related]
20. PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.
Peters S; Kerr KM; Stahel R
Cancer Treat Rev; 2018 Jan; 62():39-49. PubMed ID: 29156447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]